The current study aims to investigate Sitagliptin and vildagliptin efficacy and safety compared to metformin as 1st line options for T2D patients.
This is a randomized case-controlled study in which drug-naive type-2 diabetic patients were divided into 3 groups and followed up for three months.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
60
Galvus 50 mg oral tablets
Januvia 100mg oral tablets
Glucophage 1000 mg oral tablets
Minya University Hospital
Minya, Egypt
Changes in glycemic parameters
serum fasting glucose (mg/dl), and 2-hr postprandial glucose (mg/dl)
Time frame: 3-months
Changes in Serum insulin (IU/l)
using enzyme immunoassay (EIA) kits
Time frame: 3-months
Insulin resistance
measured by HOMA model assessment (HOMA-IR) using the following formula: (Fasting insulin (IU/ml) × Fasting glucose (mg/dl))/405
Time frame: 3-months
Beta cell function (HOMA-B)
measured by (360 ×Fasting Insulin (IU/ ml) )/(Fasting glucose(mg/dl)-63)
Time frame: 3-months
Changes in HbA1c (%)
Changes in HbA1c (%)
Time frame: 3-months
Changes in Lipid profile
(total cholesterol, TG, HDL, and LDL) (mg/dl)
Time frame: 3-months
Changes in liver enzymes
ALT and AST (U/l)
Time frame: 3-months
Changes in Renal function tests
creatinine and urea (mg/dl)
Time frame: 3-months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.